ClinicalTrials.gg
CompletedNCT02383212Updated Jan 27, 2020

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

A Phase 1 interventional study of Cemiplimab and Hypofractionated radiotherapy in Advanced Cancer and Advanced Malignancies, sponsored by Regeneron Pharmaceuticals. Completed at 47 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-27.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
398
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.

02

Conditions studied

  • Advanced Cancer
  • Advanced Malignancies

Keywords

  • Advanced cancerous growth
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. or cytologically confirmed diagnosis of with demonstrated progression of a solid tumor (non-lymphoma) with no alternative standard-of-care therapeutic option (certain exceptions may apply).
  2. At least 1 according to (RECIST) 1.1 criteria for response assessment (certain exceptions may apply)
  3. (ECOG) performance status of 0 or 1

Key Exclusion Criteria:

  1. Ongoing or recent (within 5 years) evidence of significant disease that required treatment with systemic treatments, which may suggest risk for immune-related adverse events (irAEs). The following are not exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that required only hormone replacement or psoriasis that does not require systemic treatment.
  2. Prior treatment with an agent that blocks the programmed death-1/ programmed death-ligand 1 (/PD-L1 pathway) (certain exceptions may apply)
  3. Prior treatment with other immune modulating agents within fewer than 4 weeks prior to the first dose of cemiplimab. Examples of immune modulating agents include blockers of CTLA-4, 4-1BB (CD137), OX-40, therapeutic vaccines, or cytokine treatments.
  4. Untreated (es) that may be considered active. Patients with previously treated brain metastases may participate provided they are stable (i.e., without evidence of progression by imaging for at least 6 weeks prior to the first dose of study treatment, and any neurologic symptoms have returned to baseline), and there is no evidence of new or enlarging brain metastases, and the patient does not require any systemic for management of brain metastases within 4 weeks prior to the first dose of cemiplimab (certain exceptions may apply).
  5. Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of cemiplimab

The information provided above is not intended to contain all considerations relevant to potential participation in a clinical trial, therefore not all inclusion/ exclusion criteria are listed.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
398 participants (actual)

Study arms

  • Experimental
    Monotherapy Cohort

    Cemiplimab will be administered alone

    Drug: Cemiplimab

  • Experimental
    Dual Combination Cohorts

    Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy Doses of cemiplimab will be administered in combination with Cyclophosphamide Doses of cemiplimab will be administered in combination with Docetaxel

    Drug: Cemiplimab · Radiation: Hypofractionated radiotherapy · Drug: Cyclophosphamide · Drug: Docetaxel

  • Experimental
    Triple Combination Cohorts

    Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus Cyclophosphamide Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus GM-CSF Doses of cemiplimab will be administered in combination with Carboplatin plus Paclitaxel Doses of cemiplimab will be administered in combination with Carboplatin plus Pemetrexed Doses of cemiplimab will be administered in combination with Carboplatin plus Docetaxel

    Drug: Cemiplimab · Radiation: Hypofractionated radiotherapy · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Carboplatin · Drug: GM-CSF · Drug: Paclitaxel · Drug: Pemetrexed

  • Experimental
    Quadruple Combination Cohorts

    Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus GM-CSF plus Cyclophosphamide

    Drug: Cemiplimab · Radiation: Hypofractionated radiotherapy · Drug: Cyclophosphamide · Drug: GM-CSF

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Primary safety variables include incidence and severity of TEAEs, abnormal laboratory findings and number of participants with dose limiting toxicities (DLTs)

    Time frame: Change from baseline to week 48

  2. Incidence of abnormal laboratory findings

    Time frame: Change from baseline to week 48

  3. Number of participants with dose limiting toxicities (DLTs)

    Time frame: Change from baseline to 28 days after first dose of cemiplimab

Secondary outcomes

  1. Response Evaluation Criteria in Solid Tumors (RECIST) as measured by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)

    Time frame: Change from baseline to week 48

  2. Immune-Related Response Criteria (irRC) applied to RECIST measurements

    Time frame: Change from baseline to week 48

  3. Incidence of development of anti-cemiplimab antibodies

    Time frame: Up to week 48

  4. Antitumor activity measured by progression-free survival (PFS)

    Time frame: Up to 72 weeks

  5. Antitumor activity measured by overall survival

    Time frame: Up to 249 weeks

07

Study locations

47 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona, United States
  • Western Regional Medical Center
    Goodyear, Arizona, United States
  • Mayo Clinic
    Phoenix, Arizona, United States
  • University of Arizona Cancer Center
    Tucson, Arizona, United States
  • City of Hope National Medical Center
    Duarte, California, United States
  • The Angeles Clinic and Research Institute
    Los Angeles, California 90025, United States
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California, United States
  • Stanford University
    Stanford, California, United States
  • Sarah Cannon Research Institute at HealthONE
    Denver, Colorado, United States
  • Norwalk Hospital
    Norwalk, Connecticut, United States
  • Georgetown University Medical Center
    Washington, District of Columbia, United States
  • H Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida, United States
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia, United States
  • University of Chicago
    Chicago, Illinois, United States
  • Indiana University
    Indianapolis, Indiana, United States
  • University of Kansas Cancer Center
    Fairway, Kansas, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts, United States
  • Barbara Ann Karmanos Cancer Center
    Detroit, Michigan, United States
  • Washington University School of Medicine Siteman Cancer Center
    Saint Louis, Missouri, United States
  • Nebraska Methodist Hospital
    Omaha, Nebraska, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey, United States
  • Cancer Institute of New Jersey
    New Brunswick, New Jersey, United States
  • Columbia University Medical Center
    New York, New York, United States
  • Laura & Isaac Perlmutter Cancer Center
    New York, New York, United States
  • Mount Sinai Medical Center
    New York, New York, United States
  • Weill Cornell Medical College
    New York, New York, United States
  • Duke Cancer Institute
    Durham, North Carolina, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio, United States
  • Stephenson Cancer Center
    Oklahoma City, Oklahoma, United States
  • Providence Portland Medical Center
    Portland, Oregon, United States
  • Penn State Milton S Hershey Medical Center
    Hershey, Pennsylvania, United States
  • University of Pittsburgh Medical Center Shadyside
    Pittsburgh, Pennsylvania 15232, United States
  • Miriam Hospital
    Providence, Rhode Island, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee, United States
  • Mary Crowley Cancer Research Center - Medical City
    Dallas, Texas, United States
  • Baylor College of Medicine
    Houston, Texas, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas, United States
  • START South Texas Accelerated Research Therapeutics
    San Antonio, Texas, United States
  • Northwest Medical Specialties
    Tacoma, Washington, United States
  • Peter Maccallum Cancer Centre
    Melbourne, Australia
  • Institut Catala d'Oncologia L'hospitalet
    L'Hospitalet de Llobregat, Barcelona, Spain
  • Hospital Universitario Vall d'Hebron
    Barcelona, Spain
  • Fundacion Jimenez Diaz
    Madrid, Spain
  • Hospital Universitario HM Sanchinarro-CIOCC
    Madrid, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, Spain
  • MD Anderson Cancer Center
    Madrid, Spain
08

References and documents

Publications

  • Babiker H, Brana I, Mahadevan D, Owonikoko T, Calvo E, Rischin D, Moreno V, Papadopoulos KP, Crittenden M, Formenti S, Giralt J, Garrido P, Soria A, Hervas-Moron A, Mohan KK, Fury M, Lowy I, Mathias M, Feng M, Li J, Stankevich E. Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Oncologist. 2021 Sep;26(9):e1508-e1513. doi: 10.1002/onco.13810. Epub 2021 May 22. PubMed 33942954 ↗
  • Moreno V, Garrido P, Papadopoulos KP, De Miguel Luken MJ, Gil-Martin M, Aljumaily R, Rosen LS, Rietschel P, Mohan KK, Yoo SY, Stankevich E, Lowy I, Fury MG. Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort. Lung Cancer. 2021 May;155:151-155. doi: 10.1016/j.lungcan.2021.02.034. Epub 2021 Mar 4. PubMed 33831732 ↗
  • Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, Schadendorf D, Dunn LA, Hernandez-Aya L, Chang ALS, Modi B, Hauschild A, Ulrich C, Eigentler T, Stein B, Pavlick AC, Geiger JL, Gutzmer R, Alam M, Okoye E, Mathias M, Jankovic V, Stankevich E, Booth J, Li S, Lowy I, Fury MG, Guminski A. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020 Jun;8(1):e000775. doi: 10.1136/jitc-2020-000775. PubMed 32554615 ↗
  • Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4. PubMed 29863979 ↗
  • Falchook GS, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I, Fury MG. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer. 2016 Nov 15;4:70. doi: 10.1186/s40425-016-0176-3. eCollection 2016. PubMed 27879972 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2015 to primary completion in Nov 2019, 57 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2015
First posted
Mar 9, 2015
StartActual
Feb 2, 2015
Primary completionActual
Nov 18, 2019
CompletionActual
Nov 18, 2019
Last update
Jan 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02383212
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Mar 9, 2015
Start date
Feb 2, 2015
Primary completion
Nov 18, 2019
Completion
Nov 18, 2019
Last update
Jan 27, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion